A study was conducted to determine whether the covalent chemical modification of BruceUla abortus 19 salt-extractable proteins (BCSP) and BCSP derivatives would modulate the immune responses in BALB/c mice. Salt-extractable proteins BCSP 0-70 and BCSP 70-100 were modified with acetoacetic anhydride, and recombinant proteins rBCSP20 (20 kDa), rBCSP31 (31 kDa), and rBCSP45 (45 kDa) were modified with succinic and dodecanoyl anhydrides. Four weeks after mice were vaccinated with the different preparations, principal and control mice were challenge exposed with a virulent culture of B. abortus 2308, and mice were necropsied 2 weeks later. Serum samples were obtained immediately before mice were challenge exposed and at necropsy. Sera were tested for specific immunoglobulin M (IgM) and G (IgG) antibodies by using an enzyme-linked immunosorbent assay. Acylation decreased the immune responses (increased IgG antibodies and reduced spleen CFU and splenomegaly) induced by both BCSP 0-70 and BCSP 70-100. Modification of the recombinant proteins by dodecanoyl and succinic anhydrides had no effect on the protection induced; however, the IgG serologic responses to the homologous and heterologous proteins were altered. Monophosphoryl lipid A markedly enhanced the immunogenicity of BCSP 0-70.
Brucellosis is an important zoonotic disease (35, 42) . In addition to causing health problems in humans, certain members of the genus Brucella are of tremendous economic importance to the food animal industry (35) . For example, Brucella abortus, which causes abortion and infertility in cattle, was once possibly the most costly disease to the cattle industry in the United States. Although large sums of money and many different approaches have been directed at prevention, control, and eradication of brucellosis, the disease still is a problem. The most important need at present is a highly (>90%) effective and safe one-dose vaccine.
Effective vaccines presently used to control and prevent infection in cattle consist of either whole-cell killed preparations or attenuated live cultures. Subunit vaccines have been used but are not highly effective in protecting cattle from subsequent infection and disease (8, 41) . Factors which usually influence the development of immunity against brucellosis in mice are related to the nature and dose of immunogen and the manner in which the immunizing epitopes are presented to the host's immune surveillance system (2, 3, 5, 10, 19, 20, 27, 31, 32) . The overall immunity induced involves both cell-mediated and humoral antibody effects, which probably act together in preventing and eliminating infection. However, the effects might not always act together and sometimes may be antagonistic to each other, as has been reported for other diseases (12, 15) .
It is generally accepted that immunity in brucellosis is mostly due to cellular immunity mechanisms (2, 7, 13, 27) . The reason subunit vaccines are less effective than whole-cell vaccines may be due to the lack of constitutive cofactors of the former that are inherent in whole-cell vaccines. The extracting process used for fractional vaccines may also cause chemical and physical rearrangements of the immunizing epitopes. These induced rearrangements might mask or otherwise inactivate the protective epitopes in subunit vaccines, thereby making them ineffective for cell-mediated or humoral antibody responses.
Because immunity in brucellosis is due to both cell-mediated and humoral effects, both B-and T-cell responders must be considered when subunit vaccines are used (2, 7, 27, 34) . Because of this, an important question in the development of subunit vaccines is whether the different components can be manipulated to give specific epitopic responses. Some investigators (1, 15, 18, 22, (32) (33) (34) suggest that chemical modifications of nonimmunogenic or poorly immunogenic substances can convert them to highly effective immunogens, while others (9, (22) (23) (24) reported that immunization with chemically modified antigens favors cell-mediated responses whereas unmodified antigens tend to elicit humoral responses. In our laboratory, unmodified protein antigens were not highly effective against infection by B. abortus although they usually induced excellent humoral antibody responses (28-30, 39, 40) .
The objective in this study was to determine whether covalent chemical modification of B. abortus salt-extractable and recombinant derived proteins would enhance the immune responses of BALB/c mice against challenge exposure with a virulent culture of B. abortus 2308.
MATERUILS AND METHODS
Experimental design. The study consisted of two experiments. In experiment 1, the immune responses induced in principal mice by different doses of acylated and nonacylated salt-extractable Brucella cell surface proteins (BCSP 0-70 and BCSP 70-100) were determined. In experiment 2, the immune responses induced by succinic and dodecanoyl anhydridemodified recombinant proteins rBCSP20, rBCSP31, and rBCSP45 were determined. Experiment 1 was designed specifically to compare the immunity induced by BCSP 0-70 and BCSP 70-100. These salt-extractable proteins were modified with acetoacetic anhy- (38, 39) indicated that the extractable proteins BCSP20, BCSP31, and BCSP45 which were isolated from BCSP 0-70 were partially immunogenic in laboratory animals. However, questions arose concerning possible contamination of the proteins by brucellar lipopolysaccharide (LPS) that was not eliminated during the isolation process. The recombinant proteins, derived from the extracted proteins of BCSP 0-70 and used in the present study, are presumed to be free of brucellar LPS. These proteins did not induce protection in mice when used without adjuvant or chemical modification (28, 29) . The immunity induced by BCSP 0-70, the progenitor of the subfractional proteins, was enhanced by modification with dodecanoyl anhydride (8, 39) . Results in other reports (22, 32, 33) Isolation of BCSP. BCSP 0-70 was isolated from washed methanol-inactivated B. abortus 19 as previously described (37) (38) (39) and modified (4) . Briefly, cells were grown in liquid culture, collected by filtration, washed with 0.15 M NaCl solution, and inactivated by addition of 2 volumes of methanol to 1 volume of cell suspension. The cell suspension was stirred overnight at 5°C and then allowed to stand at 5°C for 1 week, with occasional stirring. The suspension was centrifuged at 12,000 x g for 1 h, the cells were resuspended in a hypertonic salt solution, and the proteins were extracted at 5°C by gently stirring for 16 h. The extraction procedure was repeated, and the extracts were combined, concentrated by freeze-drying, dialyzed, and precipitated by ammonium sulfate at 70% saturation. BCSP 70-100 was prepared in the same way as was BCSP 0-70 except that it was precipitated by using ammonium sulfate at 100% saturation, using the supernatant solution from the 70% ammonium sulfate precipitation step. The precipitated proteins were dissolved in and dialyzed against 5 mM NH4HCO3. Protein concentration was determined by the Lowry procedure (14) . The BCSP was stored at -70°C until used.
Isolation of recombinant proteins. BCSP31 was isolated and purified as previously described (6, 17) , using a two-step procedure consisting of detergent extraction followed by ionexchange chromatography. The other recombinant proteins (rBCSP20 and rBCSP45) were isolated and purified by a similar procedure that was modified so that the recombinant protein was bound to the ion-exchange resin at low ionic strength (5 to 10 mM NaCl) and was specifically eluted in an increasing salt gradient.
Isolation of LPS. The LPS used for the vaccine and antigen in the ELISA was extracted from B. abortus 2308 by a butanol extraction procedure followed by proteinase K (E. Merck, Darmstadt, Germany) digestion as described previously (26) . The preparation contained less than 1% protein.
Chemical modification of proteins. The BCSP 0-70 and BCSP 70-100 proteins were modified with acetoacetic anhydride, and the rBCSP fractions were modified with dodecanoyl anhydride and succinic anhydride (11, 16, 18, 32, 33) . The extent of amino group modification was determined with trinitrobenzene sulfonic acid (11) .
Adjuvant. Nontoxic MPL was obtained from a commercial source (Ribi Immunochem Research, Inc., Hamilton, Mont.) and was isolated from a Salmonella typhimurium Re mutant. The MPL was stored at 4°C until thawed and used in the vaccines at a dose of 50 jig per dose.
Vaccination. Before inoculation of mice, the frozen vaccines were thawed and diluted with 0.15 M NaCl solution to obtain the desired concentration of each vaccine (Tables 1 and 2 ). Mice were vaccinated by inoculating each mouse with 0.2 ml of the respective vaccine intraperitoneally. Control mice were inoculated with 0.15 M NaCl as the placebo.
Challenge exposure. Four weeks (day 28) after vaccination, mice were challenge exposed with a virulent culture of B. abortus 2308. Each mouse was given approximately 104 CFU intraperitoneally in 0.2 ml of saline solution.
Serologic examination. Serum immunoglobulin M (IgM) and G (IgG) antibody concentrations against the different antigens were determined by using sera from mice (Tables 1   0. and 2) on the day (day 28) mice were challenge exposed and 2 weeks later (day 42) at necropsy, using an ELISA (29, 30, 36, 40) . Results of BCSP, LPS, and recombinant protein-specific IgM and IgG antibody concentrations are expressed as absorbance units (A41J/A450) and were obtained by using an ELISA plate reader (Dynatech Laboratories, Alexandria, Va.).
Culture examination of the spleen. The CFU of B. abortus per spleen and mean spleen weights were determined as previously described (28) (29) (30) .
Analysis of data. Statistical differences in spleen weights, CFU, and specific serum IgM and IgG concentrations were analyzed by using the Tukey-Kramer multiple comparison tests with the InStat program (GraphPad Software, San Diego, Calif.).
RESULTS
The results of two experiments are presented. In experiment 1, BCSP 0-70 and BCSP 70-100 were compared with their respective acetoacetylated proteins as immunogens for murine brucellosis. In experiment 2, the recombinant proteins rBCSP20, rBCSP31, and rBCSP45, which constitute BCSP 0-70 and BCSP 70-100, are compared with succinylated and dodecanoylated recombinant proteins as vaccines. Experiment 1. Mice in groups 4, 6, 8, 14, 16, 19 , and 20 (P < 0.001), groups 7, 9, and 15 (P < 0.01), and groups 2 and 5 (P < 0.05) had CFU that were less than that of mice (group 1) given the placebo ( Table 1 ). The CFU of other mice (groups 3, 10 to 13, 17, and 18) were not significantly (P > 0.05) different from CFU of mice given the placebo. As indicated by the P values, the CFU of mice given BCSP 0-70 or BCSP 70-100 was lower than the CFU of mice given acylated BCSP 0-70 or acylated BCSP 70-100. When the spleen weight of mice given placebo (group 1) was compared with spleen weights of other mice, all groups were different (P < 0.001) except groups 11 and 18 (P > 0.05). The greatest CFU reduction occurred in mice given 5.0 ,ug of BCSP 0-70 plus MPL (group 20), but the spleen weights of the two groups (groups 19 and 20) which were given 5.0 ,ug of BCSP 0-70 were similar.
The IgM and IgG antibody concentrations in prechallenge exposure sera were determined by ELISA using LPS, BCSP 0-70, and BCSP 70-100 antigens (Fig. 1) . When LPS was used as the test antigen for IgM antibody concentrations, only groups 8 and 9 (P < 0.001), 4 and 6 (P < 0.01), and 7 (P < 0.05) were different from mice given the placebo (Fig. 1A) . When the IgG antibody concentration of group 1 mice was compared with those of other groups, only groups 6 to 9 (P < 0.001), 4 (P < 0.01), and 20 (P < 0.05) were different (Fig. 1D) . When BCSP 0-70 was used as the test antigen for IgM antibody concentrations, only groups 4 and 6 to 9 (P < 0.001) and groups 14 and 16 (P < 0.05) were different from mice given the placebo (Fig. 1B) . When the IgG antibody concentrations were compared, only groups 6 and 8 (P < 0.01) were different from mice given the placebo (Fig. 1E ). When BCSP 70-100 was used as the test antigen for IgM antibody concentration, groups 5, 7, 9, and 14 (P < 0.001), 4 and 15 (P < 0.01), and 12 (P < 0.05) were different from mice given the placebo (Fig. 1C) . When the IgG antibody concentrations were compared, only group 7 (P < 0.05) was different from mice given the placebo (Fig. 1F) . The IgM and IgG antibody concentrations in postchallenge exposure sera were determined with ELISA using LPS, BCSP 0-70, and BCSP 70-100 as test antigens (Fig. 2) . When LPS was used as the test antigen to compare the IgM antibody concentrations, only groups 19 and 20 (P < 0.001) were different from mice given the placebo (Fig. 2A) . When the IgG antibody concentrations were compared, groups 5 to 9 and 13 to 17 (P < 0.001) were different from mice given the placebo (Fig. 2D) . When BCSP 0-70 was used as the test antigen to compare the IgM antibody concentrations, only groups 19 and 20 (P < 0.001) were different from mice given the placebo (Fig. 2B) . When the IgG antibody concentrations were compared, groups 6 to 9 and 15 to 17 (P < 0.001) and group 5 (P < 0.05) were different from mice given the placebo (Fig. 2E ). When BCSP 70-100 was used as the test antigen to compare the 1gM antibody concentrations, groups 5, 7 to 9, 14, and 17 (P < 0.001) and groups 12 and 16 (P < 0.01) were different from mice given the placebo (Fig. 2C) . When the IgG antibody concentrations were compared, groups 7 to 9 (P < 0.001) and group 15 (P < 0.01) were different from mice given the placebo (Fig. 2F) . The concentrations of IgG and IgM were higher when the homologous antigen was used in ELISA than when the heterologous antigens were used (Fig. 2) . Experiment 2. When the spleen CFU and splenic weight values of mice vaccinated with modified or nonmodified recombinant protein vaccines were compared with those of mice given the placebo, there were no significant (P > 0.05) differences (Table 2 ). Mice vaccinated with LPS, which was used as a positive control, had CFU and splenic weights significantly (P < 0.001) lower than those of other mice.
When the prechallenge exposure sera were examined by ELISA, there were increases in IgG and IgM concentrations in all vaccinated mice, especially against the homologous antigens, compared with mice given the placebo (Fig. 3) . The highest IgG antibody concentrations were in sera of mice vaccinated with nonmodified homologous protein. Some sera had higher IgM concentrations against heterologous antigens than against the homologous antigens ( Fig. 3C and F) .
When LPS was used as the test antigen to compare the IgM antibody concentrations, only group 2 (P < 0.001) was different from mice given the placebo (Fig. 3A) . When the IgG antibody concentrations were compared, group 2 (P < 0.001) and groups 3, 5, and 7 to 9 (P < 0.05) were different from mice given the placebo (Fig. 3D) . When BCSP 0-70 was used as the test antigen to compare the IgM concentrations, group 10 (P < 0.01) was different from mice given the placebo, and groups 3, 5, 7, and 9 (P < 0.01) and groups 4, 6, 8, and 10 (P < 0.05) were different from group 11 (Fig. 3B) . When the IgG antibody concentrations were compared, only group 2 (P < 0.05) was different from mice given the placebo (Fig. 3E) (Fig. 4) . When LPS was used as the test antigen for IgM antibody concentrations, only groups 2, 3, and 6 (P < 0.001), 4 (P < 0.01), and 5 and 7 (P < 0.05) were different from mice given the placebo (Fig.  4A ). Groups 2, 3, and 6 (P < 0.01) were different from group 9 (vaccinated with rBCSP45). When the IgG antibody concentrations were compared, groups 3 to 8 and 10 (P < 0.001) and groups 2 and 9 (P < 0.01) were different from mice given the placebo (Fig. 4D) . When BCSP 0-70 was used as the test antigen for IgM antibody concentrations, group 7 (P < 0.01) and groups 4 and 6 (P < 0.05) were different from mice given the placebo (Fig. 4B) . Group 9 was different from groups 7 (P < 0.01) and 6 (P < 0.05). When the IgG antibody concentrations were compared, no group (P > 0.05) was different from mice given the placebo (Fig. 4E) . Groups 8 and 9 (P < 0.05) were different from group 6. When rBCSP20 was used as the test antigen to compare the IgM antibody concentrations, no group (P > 0.05) was different from mice given the placebo (Fig. 4C ). Group 9 differed from groups 4 and 6 (P < 0.01) and group 7 (P < 0.05). When rBCSP20 was used to compare the IgG antibody concentrations, groups 3 and 9 (P < 0.001), 6 (P < 0.01), and 2 (P < 0.05) were different (Fig. 4F) . When rBCSP31 was used as the test antigen to compare the IgM antibody concentrations, the P values for all groups were greater than 0.05 (Fig. 4C) . When rBCSP31 was used to compare the IgG antibody concentrations, no group (P > 0.05) was different from mice given the placebo (Fig. 4F) . The groups (P > 0.05) were also not different from each other. When rBCSP45 was used as the test antigen to compare the IgM antibody concentrations, all groups (P < 0.001) were different from mice given the placebo (Fig. 4C ). There were no differences (P > 0.05) between the other groups. When rBCSP45 was used to compare the IgG antibody concentrations, groups 8 and 11 (P < 0.001) and group 5 (P < 0.01) were different from mice given the placebo (Fig. 4F) . Group 2 was different from group 8 (P < 0.01). Group 3 was different from groups 7 and 11 (P < 0.001). Group 4 was different from groups 5, 8, and 11 (P < 0.001). Group 5 was different from groups 7, 9, and 10 (P < 0.001) and 6 (P < 0.01). Group 6 was different from groups 9 and 11 (P < 0.001). Group 7 was different from groups 8 and 11 (P < 0.001). Group Group  FIG. 3 . Prechallenge exposure ELISA results for mice vaccinated with dodecanoyl anhydride-and succinic anhydride-modified recombinant proteins rBCSP20, rBCSP31, and rBCSP45 and the corresponding nonmodified recombinant proteins. Mice in group 1 were given 0.2 ml of 0.15 M NaCl. Mice in group 2 were given 0.5 jig of LPS. Mice in groups 3, 4, and 5 were given 10.0 jig of nonmodified rBCSP20, succinic anhydride-modified rBCSP20, and dodecanoyl anhydride-modified rBCSP20, respectively. Mice in groups 6, 7, and 8 were given 10.0 ,ug of nonmodified rBCSP31, succinic anhydride-modified rBCSP31, and dodecanoyl anhydride-modified rBCSP31, respectively. Mice in groups 9, 10, and 11 were given 10.0 ,ug of nonmodified rBCSP45, succinic anhydride-modified rBCSP45, and dodecanoyl anhydride-modified rBCSP45, respectively. The results are depicted as ELISA absorbance (103) at A41JA450, using the specific antigen. different from group 11 (P < 0.001), and group 10 was different from group 11 (P < 0.001).
DISCUSSION
The results obtained in experiment 1 indicate that acylation of BCSP 0-70 or BCSP 70-100 does not enhance their immunogenicity for mice against B. abortus infections. Contrariwise, acylation caused decreases in the immune responses of reduced spleen CFU and splenomegaly compared with mice that received nonacylated proteins. The greatest reduction in protection occurred in mice that received low doses of the acylated proteins compared both with mice given nonacylated proteins at the same concentration and with mice given the placebo. Possibly, at low doses, the concentrations of unmodified epitopes were too low to induce protective immunity or the epitopes interfered with the immunogenesis, whereas at higher doses, the number of nonmodified protective epitopes was sufficient to induce protective immunity in spite of the presence of acylation effects. In each case in which equal doses of acylated and nonacylated proteins were given, the group that received the acylated protein, regardless of the dose, had higher CFU and spleen weights. This finding also might mean that the number of unmodified epitopes was the critical factor which determined the difference; unfortunately, we did not titrate the dose range for these acylated proteins. Acylation of proteins was reported to increase the protective immunity of BCSP vaccines, but apparently the protective immunity was dependent on the percent modification of available primary amino groups of the proteins (39).
The linear increases in the protection corresponding to increased doses of both BCSP 0-70 and BCSP 70-100 whether the proteins were acylated or not indicate that dose-response relationships are important with Brucella protein vaccines (5, 30, 40) . The results also indicate that BCSP 0-70, at the same dose, is 10 times more effective than BCSP 70-100. The protective epitopes involved with both BCSP 0-70 and BCSP 70-100 immunity are presumed to be identified closely with similar epitopes found in LPS. Although we assume that our method of preparing the proteins eliminated LPS and given the fact that the proteins were free of 3-deoxy-D-mannooctulosonic acid, a prequisite for LPS presence, it is still possible that one or more common but unidentified immunizing epitopes were present in these vaccines. We feel, however, that the common protective epitopes in LPS and the proteins might not Postchallenge exposure ELISA results for mice vaccinated with dodecanoyl anhydride-and succinic anhydride-modified recombinant proteins rBCSP20, rBCSP31, and rBCSP45 and the corresponding nonmodified recombinant proteins. Mice in group 1 were given 0.2 ml of 0.15 M NaCl. Mice in group 2 were given 0.5 ,ug of LPS. Mice in groups 3, 4, and 5 were given 10.0 ,ug of nonmodified rBCSP20, dodecanoyl anhydride-modified rBCSP20, and succinic anhydride-modified rBCSP20, respectively. Mice in groups 6, 7, and 8 were given 10.0 jig of nonmodified rBCSP31, dodecanoyl-modified rBCSP31, and succinic anhydride-modified rBCSP31, respectively. Mice in groups 9, 10, and 11 were given 10.0 ,ug of nonmodified rBCSP45, dodecanoyl anhydride-modified rBCSP45, and succinic anhydride-modified rBCSP45, respectively. The results are depicted as ELISA absorbance (103) at A410A45O, using the specific antigen. zation with chemically modified antigens favors cell-mediated responses, while unmodified antigens tend to elicit humoral antibody responses (9, (21) (22) (23) (24) . Consequently, these results suggest that although acylation lowered IgG antibody concentrations, the lowering was not directly related to protection because in brucellosis, protection is mainly dependent upon cell-mediated immunity.
We suggest that the lack of direct relationship between increased protection and increased IgG antibody concentrations is due to the fact that the protective subclass found in IgG that affects brucellar immunity in BALB/c mice is IgG3 and the ELISA results involve, in addition to IgG3, subclasses IgGl, IgG2a, and IgG2b. Unpublished results in our laboratory indicated that the better-protected (P < 0.001) vaccinated mice had higher IgG3 antibody concentrations in their prechallenge exposure sera than did vaccinated and partially protected (P < 0.05) mice with lower IgG3 antibody concentrations or nonprotected (P > 0.05) nonvaccinated mice. Another report (25) of results from our laboratory indicated that the injection of monoclonal IgG3 antibodies into BALB/c mice provided partial protection against B. abortus infection.
When the IgG isotype distribution and concentrations in the prechallenge exposure sera were determined (data not shown), the sera of mice (groups 19 and 20) given MPL had the highest IgG3 concentrations and the mice (group 20) also given BCSP 0-70 (experiment 1, Table 1 ) were the best-protected mice; group 20 mice had significant (P < 0.001) reduction in CFU and splenomegaly compared with other mice in experiment 1. Results in another study (40) indicated that MPL was an excellent immune response modifier in BCSP 0-70 vaccines but MPL did not enhance the immunogenicity of LPS vaccines. The role of IgG3 and the mechanisms involved when MPL is used as an immune response modifier in vaccines are beyond the scope of this report.
The results from experiment 2 indicated that the modification of the recombinant proteins rBCSP20, rBCSP31, and rBCSP45 by succinic and dodecanoyl anhydrides altered their induction of serologic responses to homologous as well as heterologous antigen as determined by ELISA. Others (18, 21, 22, 33) have reported that modification by these chemical compounds cause changes in the immune responses induced. The vaccines prepared from recombinant proteins, both modified or nonmodified, however, although inducing increased IgG and IgM antibody concentrations in the sera of vaccinated mice, did not enhance the protective responses of reduced spleen CFU and splenomegaly in challenge-exposed mice compared with mice given the placebo. This lack of correlation might indicate that the proteins do not contain specific epitopes for cell-mediated immune functions that are found in LPS or BCSP fractions although the modifications enhanced the recombinant protein to produce antibodies. Results in a related study (unpublished data) in our laboratory indicated that rBCSP45 derived from BCSP 0-70 and an uncharacterized subfraction from BCSP 70-100 induced significant (P < 0.01) protection in mice when MPL plus these proteins were used in vaccines. This probably means that increased antibody concentrations alone are not able to cause reduced CFU and splenomegaly significantly and some additional factor such as LPS or VOL. 62, 1994 5333 TL v.,
.< OA MPL is also needed to modulate the cell-mediated protective effects. It is well established that the immunity in brucellosis is due to cell-mediated responses (2, 7, 13) .
